Research Article| Volume 36, ISSUE 1, P1-7, April 1989

Influence of propranolol on platelet aggregation and thromboxane B2 production from platelet-rich plasma and whole blood

      This paper is only available as a PDF. To read, Please Download here.


      The beta-adrenoceptor antagonist propranolol is used in the therapy of hypertension and ischemic heart disease. The aim of our study was to evaluate the effects of this drug on platelet aggregation and on synthesis of thromboxane B2 (the stable metabolite of Thromboxane A2) from platelet rich plasma (PRP), whole blood samples and during spontaneous clotting. The results indicate that propranolol at concentrations near the therapeutic range, significantly inhibit collagen and thrombin-induced platelet aggregation and TxB2 synthesis from PRP. Furthermore the drug demonstrates inhibitory activity on B-TG release and TxB2 production from whole blood samples and on spontaneous clotting. The results suggest that some benefits of propranolol in the treatment of patients with coronary artery disease or cardiovascular conditions associated with platelet hyperaggregability may also be related to interference with platelet activation “in vivo” and with TxA2 generation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Prostaglandins, Leukotrienes and Essential Fatty Acids
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kerry R
        • Scrutton MC
        Platelet beta-adrenoceptors.
        Br J Pharmacol. 1983; 79: 681
        • Kerry R
        • Scrutton MC
        Platelet adrenoceptors.
        in: Longenecker GL the platelets: Physiology and Pharmacology. Academic Press, Orlando1985: 113
        • Feinstein MB
        • Zavoico BG
        • Halenda SP
        Calcium and cyclic AMP antagonistic modulators of platelet function.
        in: Longenecker GL The Platelets: Physiology and Pharmacology. Academic Press, Orlando1985: 237
        • Jurgensen HJ
        • Dalsgaard-Nielsen J
        • Kjollej EV
        • Gormsen J
        Effect of long term beta-blockade with alprenolol on platelet function and fibrinolytic activity in patients with coronary heart disease.
        Eur J Clin Pharmacol. 1981; 20: 242
        • Hansen KW
        • Klysner R
        • Geisler A
        • Knudsen JB
        • Glaeser S
        • Gormsen J
        platelet aggregation and beta-blockers.
        Lancet. 1982; 1: 224
        • Winther K
        • Knudsen JB
        • Gormsen J
        • Jensen J
        Effect of metoprolol and propranolol on platelet aggregation and cAMP levels in hypertensive patients.
        Eur J Clin Pharmacol. 1986; 29: 561
        • Bucher HW
        • Stucki P
        The effect of various beta-receptor blocking agents on platelet aggregation.
        Experientia. 1978; 25: 280
        • Weksler BB
        • Gillick M
        • Pink J
        Effect of propranolol on platelet function.
        Blood. 1977; 49: 185
        • Campbell WB
        • Johnson AR
        • Callahan KS
        • Robert RM
        Antiplatelet activity of beta-adrenergic antagonists: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment.
        Lancet. 1981; 2: 1382
        • Callahan KS
        • Johnson AR
        • Campbell WB
        Enhancement of the antiaggregatory activity of prostacyclin by propranolol in human platelets.
        Circulation. 1985; 71: 1237
        • Pattison A
        • Eason CT
        • Bonner FW
        The in vitro effect of amrinone on thromboxane B2 synthesis in human whole blood.
        Thromb Res. 1986; 42: 817
        • Beta-blocker Heart Attack Trial Research Group
        A randomized trial of propranolol in patients with acute myocardial infarction: Mortality results.
        JAMA. 1982; 247: 1707
        • Born GVR
        Aggregation of blood platelets by adenosine diphosphate and its reversal.
        Nature. 1962; 194: 927
        • Weiss HJ
        • Rogers J
        Thrombocytopenia due to abnormalities in platelet release-reaction.
        Blood. 1972; 39: 2
        • Thompson SG
        • Vickers MV
        Methods in dose response platelet aggregometry.
        Thrombosis and Haemostasis. 1985; 54: 216
        • Meade TW
        • Vickers MV
        • Thompson SG
        • Stirling Y
        • Haines AP
        • Miller GJ
        Epidemiological characteristics of platelet aggregability.
        Br Med J. 1985; 290: 428
        • Armitage P
        Statistical methods in medical research.
        Blackwell, Oxford1971
        • Shand DJ
        • Nuckolls EM
        • Oats JA
        Plasma propranolol levels in adults.
        Clin Pharmacol Ther. 1970; 11: 112
        • Vanderhoe JV
        • Feinstein MB
        Local anesthetics, chlorpromazine and propranolol inhibit stimulus-activation of phospholipase A2 in human platelets.
        Mol Pharmacol. 1978; 16: 171
        • Volpi M
        • Sha'afi RJ
        • Epstein PM
        • Andrenyak DM
        • Feinstein MB
        Local anesthetics, mepacrine and propranolol are antagonists of calmodulin.
        in: Proc Natl Acad Sci. 78. 1981: 795
        • Saniabadi AR
        • Belch JJF
        • Lowe GDO
        • Barbenel JC
        • Forbes CD
        Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
        Haemostasis. 1987; 17: 147
        • Packham MA
        • Mustard FJ
        Pharmacology of platelet-affecting drugs.
        Circulation. 1980; 62: V-26-V-41
        • Hawiger J
        Formation and regulation of platelet and fibrin haemostatic plug.
        Human Pathology. 1987; 18: 111
        • Zucker MB
        • Borrelli J
        Platelet lumping produced by connective tissue suspensions and by collagen.
        in: Proc Soc Exp Biol Med. 109. 1963: 779
        • Kinlough-Rathbone RL
        • Packham MA
        • Reimers HJ
        • Cazenave JP
        • Mustard JF
        Mechanisms of platelet shape-change, aggregation and release induced by collagen, thrombin and A23187.
        J Lab Clin Med. 1977; 90: 707
        • Chignard M
        • Le Couedic JP
        • Vargaftig BB
        • Benveniste J
        Platelet activating factor (PAF-Acether) secretion from platelets: effect of aggregating agents.
        Br J Haematol. 1980; 46: 455
        • Timmons S
        • Kloczewiak M
        • Hawiger J
        ADP-dependent common receptor mechanism for binding of Von Wille-brand and fibrinogen to human platelets.
        in: Proc Natl Acad Sci. 81. 1984: 4935
        • Hamberg M
        • Svensson J
        • Samuelsson B
        Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides.
        in: Proc Nat Acad Sci. 72. 1975: 2994
        • Gorman RR
        Modulation of human platelet function by prostacyclin and thromboxane A2.
        in: Fed Proc. 32. 1979: 83
        • Robertson RM
        • Robertson D
        • Roberts LJ
        • Maas RL
        • Fitzgerald GH
        • Friesinger GC
        • Oates JA
        Thromboxane A2 in vasotonic angina pectoris.
        N Engl J Med. 1981; 304: 992
        • Hirsh PD
        • Hillis LD
        • Campbell WB
        • Firth BG
        • Willerson JT
        Releasae of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.
        N Engl J Med. 1981; 304: 685
        • Metha J
        • Metha P
        Significance of platelet function and Thromboxane B2 levels across the myocardial vascular bed in man.
        Acta Med Scand. 1981; 210: 111
        • Neri Serneri GG
        • Abate R
        • Panetta A
        • Pinto S
        • Favillo S
        • Prisco D
        • Gensini GF
        Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina.
        Thromb Res. 1987; 46: 303
        • Coker SJ
        • Parrat JR
        • Ledingham IM
        • Zeitling IJ
        Evidence that thromboxane contributes to ventricular fibrillation induced by reperfusion of the ischaemic myocardium.
        J Molec Cell Cardiol. 1982; 14: 483